Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

NCT01964651 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-42165279 50 mg
DRUG: JNJ-42165279 100 mg
DRUG: JNJ-42165279 30 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC